The Yale University Office of Cooperative Research has granted an exclusive license to Chinese biopharmaceutical company SurExam Life Science & Technology for the commercialization of the university's blood testing technology for epithelial ovarian cancer (EOC).
The Yale technology for EOC detection is based on analysis of a collection of known serum proteins associated with cancer biology. Each protein marker is assayed using a routine ELISA assay, and then the panel of results is scored.
"SurExam is delighted to license the Yale technology for early detection of ovarian cancer in China — and to help to improve the health of women in our country," said Dr Jiasen Xu, CEO of SurExam. "I hope SurExam's work will facilitate future collaboration between Yale and Chinese biotechnology companies, he added."
In the US, EOC is the fourth most common cancer in women and the leading cause of gynecologic cancer death. EOC affects approximately 25,000 women each year, and more than 16,000 will die from the disease.